AXIM Biotechnologies, Inc. (AXIM) stock
AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
AXIM Biotechnologies r&d expenses
Research and development expenses are spending on new products and technology.
AXIM Biotechnologies's R&D Expenses for the twelve months ending Jun 30, 2024 was $90.64K, down 29.6% year over year. For fiscal 2023 it was $125.50K, down 18.3% from the year before. The highest annual figure on record is $2.06M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $125.50K | -18.3% |
| FY2022 | Dec 31, 2022 | $153.70K | -46.0% |
| FY2021 | Dec 31, 2021 | $284.87K | -33.2% |
| FY2020 | Dec 31, 2020 | $426.71K | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $2.06M | +52.0% |
| FY2017 | Dec 31, 2017 | $1.35M | +474.3% |
| FY2016 | Dec 31, 2016 | $235.58K | -58.8% |
| FY2015 | Dec 31, 2015 | $571.46K | – |
| FY2014 | Dec 31, 2014 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | $4.06K | -88.1% |
| Q1 FY2024 | Mar 31, 2024 | $15.50K | -23.8% |
| Q4 FY2023 | Dec 31, 2023 | $36.37K | -18.5% |
| Q3 FY2023 | Sep 30, 2023 | $34.71K | +16.8% |
| Q2 FY2023 | Jun 30, 2023 | $34.07K | -3.1% |
| Q1 FY2023 | Mar 31, 2023 | $20.34K | -54.0% |
| Q4 FY2022 | Dec 31, 2022 | $44.61K | -35.0% |
| Q3 FY2022 | Sep 30, 2022 | $29.72K | -55.8% |
| Q2 FY2022 | Jun 30, 2022 | $35.17K | -26.8% |
| Q1 FY2022 | Mar 31, 2022 | $44.19K | -56.2% |
| Q4 FY2021 | Dec 31, 2021 | $68.59K | -64.1% |
| Q3 FY2021 | Sep 30, 2021 | $67.26K | -38.4% |
| Q2 FY2021 | Jun 30, 2021 | $48.07K | -60.4% |
| Q1 FY2021 | Mar 31, 2021 | $100.95K | – |
| Q4 FY2020 | Dec 31, 2020 | $191.28K | – |
| Q3 FY2020 | Sep 30, 2020 | $109.14K | – |
| Q2 FY2020 | Jun 30, 2020 | $121.44K | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $532.68K | -21.5% |
| Q4 FY2018 | Dec 31, 2018 | $354.19K | -31.5% |
| Q3 FY2018 | Sep 30, 2018 | $350.59K | -44.6% |
| Q2 FY2018 | Jun 30, 2018 | $672.74K | +968.7% |
| Q1 FY2018 | Mar 31, 2018 | $678.66K | +383.5% |
| Q4 FY2017 | Dec 31, 2017 | $516.98K | +621.7% |
| Q3 FY2017 | Sep 30, 2017 | $632.67K | +621.3% |
| Q2 FY2017 | Jun 30, 2017 | $62.95K | +39.7% |
| Q1 FY2017 | Mar 31, 2017 | $140.37K | +350.2% |
| Q4 FY2016 | Dec 31, 2016 | $71.63K | +11.2% |
| Q3 FY2016 | Sep 30, 2016 | $87.72K | -34.1% |
| Q2 FY2016 | Jun 30, 2016 | $45.05K | -82.1% |
| Q1 FY2016 | Mar 31, 2016 | $31.18K | -50.2% |
| Q4 FY2015 | Dec 31, 2015 | $64.44K | – |
| Q3 FY2015 | Sep 30, 2015 | $133.09K | – |
| Q2 FY2015 | Jun 30, 2015 | $251.03K | – |
| Q1 FY2015 | Mar 31, 2015 | $62.67K | – |
| Q4 FY2014 | Dec 31, 2014 | $0 | – |
| Q3 FY2014 | Sep 30, 2014 | $0 | – |
See a number that looks wrong?